Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.45% | 30.08% | 18.34% | 1.69% | 10.15% |
| Total Depreciation and Amortization | -20.76% | -13.80% | 39.33% | 61.29% | 84.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -19.52% | 193.92% | 43.76% | 219.99% | -4.41% |
| Change in Net Operating Assets | -43.06% | -276.77% | -621.21% | -506.76% | -240.05% |
| Cash from Operations | 44.12% | 33.37% | 10.18% | 3.97% | -0.66% |
| Capital Expenditure | -227.27% | 47.18% | 52.66% | 73.88% | 98.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.56% | 3.29% | -5.74% | -8.76% | 24.03% |
| Cash from Investing | -55.06% | 28.49% | 32.31% | 56.29% | 93.95% |
| Total Debt Issued | -- | -- | 200.00% | 200.00% | -- |
| Total Debt Repaid | -600.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -49.44% | -98.48% | 441.75% | 699.31% | 1,922.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.60% | -35.54% | 194.26% | 234.40% | 132.54% |
| Foreign Exchange rate Adjustments | 38.30% | 15.13% | -156.29% | -202.60% | 27.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.35% | 28.79% | 114.96% | 100.61% | 55.60% |